Industry Experts

Ms. Dettling leads R&D efforts toward novel therapeutic designs targeting the disease microenvironment.  Before founding Fury Biosciences, Danielle served as Senior Director of Research Development at Maverick Therapeutics (acquired by Takeda in 2021), enabling the advancement of two novel T cell-engagers into Phase 1 clinical testing, the first of their class to enter clinical trials for the treatment of solid tumors.  At Pfizer, Ms. Dettling was co-inventor and program lead of Flt3-targeted CAR-T and CD3 bispecific programs for the treatment of AML.  She developed novel biotherapeutics across indications, including immuno-oncology, metabolic disease, pain, and bone metabolic disorders.